ABG
BPMC

Ally Bridge Group’s Blueprint Medicines BPMC Stock Holding History

Ally Bridge Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,192
Closed -$6.57M – 27
2025
Q1 		$6.57M Buy
74,192
+18,300
+33% +$1.79M 5.92% 6
2024
Q4 		$4.87M Sell
55,892
-50,188
-47% -$4.6M 4.18% 8
2024
Q3 		$9.81M Buy
106,080
+30,442
+40% +$3.02M 5.25% 5
2024
Q2 		$8.15M Sell
75,638
-85,312
-53% -$8.54M 4.86% 8
2024
Q1 		$15.3M Buy
+160,950
New +$13.8M 8.49% 1

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ally Bridge Group's BPMC Position: Q2 2025 in Review

Ally Bridge Group sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 74,192 shares — an estimated $6.57M sold.

Ally Bridge Group first reported a position in BPMC in Q1 2024 and held it in 5 quarters. The position peaked at $15.3M in Q1 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Ally Bridge Group reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Ally Bridge Group sold 74,192 Blueprint Medicines shares in Q2 2025, an estimated $6.57M.
  • Ally Bridge Group first reported a position in Blueprint Medicines in Q1 2024 and held it in 5 quarters.
  • Ally Bridge Group's Blueprint Medicines position peaked at $15.3M in Q1 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.